Skip to main content
Top
Published in: Journal of Cancer Survivorship 4/2017

01-08-2017 | Review

Life beyond a diagnosis of glioblastoma: a systematic review of the literature

Authors: L Gately, SA McLachlan, A Dowling, J Philip

Published in: Journal of Cancer Survivorship | Issue 4/2017

Login to get access

Abstract

Background

The median survival of glioblastoma is 12–14 months with less than 10% of patients surviving at least 2 years from diagnosis. Patients diagnosed with glioblastoma face poor prognosis, significant symptom burden, and high care needs. The aim of this study is to undertake a literature review to document the issues encountered by long-term survivors of glioblastoma, a small but important subset of patients.

Methods

MEDLINE, PsychInfo, and EMBASE were searched with core concepts: (1) glioblastoma, (2) survivor, and (3) terms pertaining to survivorship issues. A thematic analysis was undertaken of the three included studies.

Results

Long-term survivors of glioblastoma encounter neurologic deficits, impairment in cognition, psychological distress, reduced social function, and future uncertainty. These issues result in the inability to return to work and financial difficulties. Independence in activities of daily living, working memory, and overall quality of life appears to be preserved.

Conclusions

Long-term survivors of glioblastoma continue to have significant symptom burden and care needs. There is currently a paucity of literature surrounding this topic. Further research is required to accurately describe these issues in order for improved supportive care to be implemented in the community and the outpatient setting.

Implications for Cancer Survivors

Understanding the issues faced by long-term survivor of glioblastoma will provide insight into the care needs of patients as well as support networks required for patients and their carers.
Literature
1.
go back to reference Dobes M, Khurana V, Shadbolt B, et al. Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of schwannoma (2000-2008): findings of a multicentre Australian study. Surg Neurol Int. 2011;2:176.CrossRefPubMedPubMedCentral Dobes M, Khurana V, Shadbolt B, et al. Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of schwannoma (2000-2008): findings of a multicentre Australian study. Surg Neurol Int. 2011;2:176.CrossRefPubMedPubMedCentral
2.
go back to reference Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.CrossRefPubMed Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.CrossRefPubMed
3.
go back to reference Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRefPubMed Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRefPubMed
4.
go back to reference Schmidinger M, Linzmayer L, Becherer A, et al. Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. J Neuro-Oncol. 2003;63(1):55–61.CrossRef Schmidinger M, Linzmayer L, Becherer A, et al. Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. J Neuro-Oncol. 2003;63(1):55–61.CrossRef
5.
go back to reference Steinbach JP, Blaicher HP, Herrlinger U, et al. Surviving glioblastoma for more than 5 years: the patient’s perspective. Neurology. 2006;66:239–42.CrossRefPubMed Steinbach JP, Blaicher HP, Herrlinger U, et al. Surviving glioblastoma for more than 5 years: the patient’s perspective. Neurology. 2006;66:239–42.CrossRefPubMed
6.
go back to reference Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-Oncology. 2013;15(Suppl 2):ii1–ii56.CrossRefPubMedPubMedCentral Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-Oncology. 2013;15(Suppl 2):ii1–ii56.CrossRefPubMedPubMedCentral
7.
go back to reference Krex D, Klink B, Hartmann C et al. Long-term survival with glioblastoma multiforme. First published online: 4 September 2007;2596–2606. doi:10.1093/brain/awm204. Krex D, Klink B, Hartmann C et al. Long-term survival with glioblastoma multiforme. First published online: 4 September 2007;2596–2606. doi:10.​1093/​brain/​awm204.
8.
go back to reference Sacko A, Hou MM, Temgoua M, et al. Evolution of the Karnosky Performance Status throughout life in glioblastoma patients. J Neuro-Oncol. 2015;122(3):567–73.CrossRef Sacko A, Hou MM, Temgoua M, et al. Evolution of the Karnosky Performance Status throughout life in glioblastoma patients. J Neuro-Oncol. 2015;122(3):567–73.CrossRef
9.
go back to reference Giovagnoli AR, Silvani A, Colombo E, et al. Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry. 2005;76:562–8.CrossRefPubMedPubMedCentral Giovagnoli AR, Silvani A, Colombo E, et al. Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry. 2005;76:562–8.CrossRefPubMedPubMedCentral
10.
go back to reference Meyers C, Boake C. Neurobehavioral disorders experienced by brain tumor patients: rehabilitation strategies. Cancer Bull. 1993;45:362–4. Meyers C, Boake C. Neurobehavioral disorders experienced by brain tumor patients: rehabilitation strategies. Cancer Bull. 1993;45:362–4.
11.
go back to reference Sizoo E, Dirven L, Reijneveld J, et al. Measuring health-related quality of life in high-grade glioma patients at the end of life using a proxy-reported retrospective questionnaire. J Neuroonc. 2014;116(2):283–90.CrossRef Sizoo E, Dirven L, Reijneveld J, et al. Measuring health-related quality of life in high-grade glioma patients at the end of life using a proxy-reported retrospective questionnaire. J Neuroonc. 2014;116(2):283–90.CrossRef
12.
go back to reference Smoll NR, Schaller K, Gautschi OP. Long-term survival of patients with glioblastoma multiforme (GBM). J Clin Neurosci. 2013;20(5):670–5.CrossRefPubMed Smoll NR, Schaller K, Gautschi OP. Long-term survival of patients with glioblastoma multiforme (GBM). J Clin Neurosci. 2013;20(5):670–5.CrossRefPubMed
13.
go back to reference Hottinger A, Yoon H, DeAngelis L, et al. Neurological outcome of long-term glioblastoma survivors. J Neuro-Oncol. 2009;95:301–5.CrossRef Hottinger A, Yoon H, DeAngelis L, et al. Neurological outcome of long-term glioblastoma survivors. J Neuro-Oncol. 2009;95:301–5.CrossRef
14.
go back to reference Flechl B, Ackerl M, Sax C, et al. Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. J Neuro-Oncol. 2012;109:331–9.CrossRef Flechl B, Ackerl M, Sax C, et al. Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. J Neuro-Oncol. 2012;109:331–9.CrossRef
16.
go back to reference Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8(9):810–8.CrossRefPubMed Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8(9):810–8.CrossRefPubMed
17.
go back to reference Ford E, Catt S, Chalmers A, et al. Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro-Oncology. 2012;14(4):392–404.CrossRefPubMedPubMedCentral Ford E, Catt S, Chalmers A, et al. Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro-Oncology. 2012;14(4):392–404.CrossRefPubMedPubMedCentral
18.
go back to reference Boele FW, Douw L, Reijneveld JC, et al. Health-related quality of life in stable, long-term survivors of low-grade glioma. JCO. 2015;33(9):1023–9.CrossRef Boele FW, Douw L, Reijneveld JC, et al. Health-related quality of life in stable, long-term survivors of low-grade glioma. JCO. 2015;33(9):1023–9.CrossRef
19.
go back to reference Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomized phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer. 1998;34(12):1902–9.CrossRefPubMed Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomized phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer. 1998;34(12):1902–9.CrossRefPubMed
Metadata
Title
Life beyond a diagnosis of glioblastoma: a systematic review of the literature
Authors
L Gately
SA McLachlan
A Dowling
J Philip
Publication date
01-08-2017
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 4/2017
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-017-0602-7

Other articles of this Issue 4/2017

Journal of Cancer Survivorship 4/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine